Company Overview of Nestlé Health Science S.A.
Nestlé Health Science S.A. engages in the manufacture and distribution of nutritional solutions for consumers, patients, and its partners in healthcare worldwide. It offers diagnostics, devices, and drugs for inborn errors of metabolism, paediatric and acute care, obesity care, healthy ageing, and gastrointestinal and brain health; clinical nutritional solutions for metabolic disorders; diagnostics and pharmaceuticals in gastroenterology and oncology; prescription medical foods for the brain and metabolic disorders; botanical-based nutrients for gastrointestinal disorders; an assessment tool to help healthcare professionals identify cases of cow's milk protein allergy or CMPA in infants; and...
Avenue Reller 14
Founded in 2010
Key Executives for Nestlé Health Science S.A.
Chief Executive Officer and Director
Director and Chief Executive Officer of Nestlé S A
Chief Executive Officer of Accera and President of Accera
Head of Nestlé Institute of Health Sciences and Director
Compensation as of Fiscal Year 2014.
Nestlé Health Science S.A. Key Developments
Nestlé Health Science S.A. Introduces New Cow Milk Protein Allergy Assessment Tool
Apr 13 15
Nestlé Health Science S.A. has introduced an assessment tool to help healthcare professionals identify cases of cow's milk protein allergy, or CMPA, in infants. Some infants develop an allergy to cow's milk when their immune system mistakenly sees the milk protein as something the body should fight off. CMPA can cause an infant to be fussy and irritable due to an upset stomach and other symptoms. CMPA is usually difficult to diagnose because many of its symptoms are non-specific, which means its symptoms are common with other medical conditions seen in infants and children. The new Cow's Milk-related Symptom Score Tool (CoMiSS), developed by a panel of leading international experts and funded by an unrestricted grant by Nestle Health Science, is designed to help healthcare professionals identify the allergy at an earlier stage.
Nestlé Health Science Announces Executive Changes
Sep 26 14
At its meeting on 26 September 2014, the Nestlé Board of Directors supported the proposal to create a new Executive Board function. Luis Cantarell will take on the responsibility for the new Zone EMENA, a role for which he is ideally positioned considering his past experiences. Luis Cantarell will remain on the Board of Nestlé Health Science which, as President and CEO, he started and set up. Greg Behar will become CEO of Nestlé Health Science and report directly to the Nestlé Health Science Board. Greg Behar is joined Nestlé in July 2014 from Boehringer Ingelheim where he was President and CEO of Boehringer Ingelheim Pharmaceuticals Inc. These decisions have been taken effective 1 October 2014, and the new structure will be fully operational by 1 January 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries